We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

80 hedge funds and large institutions have $522M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

14% more capital invested

Capital invested by funds: $460M → $522M (+$62.1M)

3% more funds holding

Funds holding: 7880 (+2)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

4% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 26

Holders
80
Holders Change
+2
Holders Change %
+2.56%
% of All Funds
1.73%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
11
Increased
25
Reduced
26
Closed
9
Calls
Puts
Net Calls
Net Calls Change

DCPH Hedge Fund Activity: Q1 2019 in Review

80 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2019, worth a combined $522M — up 14% from $460M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new DCPH positions and 9 closed out — a net gain of 2 holders — while 25 added to existing stakes and 26 trimmed.

The largest buyer was OrbiMed, adding an estimated $30.8M. The largest seller was Norges Bank, exiting entirely with an estimated $6.97M sold.

  • 80 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2019, up from 78 in Q4 2018.
  • Funds reported $522M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 14% quarter-over-quarter.
  • 11 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 9 closed out, a net change of +2 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was OrbiMed, an estimated $30.8M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Norges Bank, an estimated $6.97M sold.

Based on aggregated 13F filings for Q1 2019.